Production (Stage)
Atossa Therapeutics, Inc.
ATOS
$0.8317
-$0.0382-4.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.10% | 26.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.68% | 12.00% | |||
| Operating Income | -3.68% | -12.00% | |||
| Income Before Tax | -5.85% | 12.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.85% | 12.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.85% | 12.21% | |||
| EBIT | -3.68% | -12.00% | |||
| EBITDA | -3.68% | -12.00% | |||
| EPS Basic | -3.79% | 12.87% | |||
| Normalized Basic EPS | -3.83% | -14.23% | |||
| EPS Diluted | -3.79% | 12.87% | |||
| Normalized Diluted EPS | -3.83% | -14.23% | |||
| Average Basic Shares Outstanding | 2.02% | 0.67% | |||
| Average Diluted Shares Outstanding | 2.02% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||